

Title (en)
PHARMACEUTICALLY ACCEPTABLE SALT OF SPHINGOSINE-1-PHOSPHATE RECEPTOR AGONIST, AND CRYSTALLINE FORM THEREOF

Title (de)
PHARMAZEUTISCH AKZEPTABLES SALZ EINES SPHINGOSIN-1-PHOSPHAT-REZEPTORAGONISTEN UND KRISTALLINE FORM DAVON

Title (fr)
SEL PHARMACEUTIQUEMENT ACCEPTABLE D'AGONISTE DU RÉCEPTEUR DE LA SPHINGOSINE-1-PHOSPHATE, ET FORME CRISTALLINE DE CELUI-CI

Publication
EP 4324827 A1 20240221 (EN)

Application
EP 22788456 A 20220413

Priority

- KR 20210048829 A 20210414
- KR 2022005378 W 20220413

Abstract (en)
The present invention relates to a pharmaceutically acceptable salt of a sphingosine-1-phosphate receptor agonist and a crystalline form thereof, and more specifically, to a potassium salt or methanesulfonate of 1-[1-chloro-6-(3-chloro-1-isopropyl-1H-indazol-5-ylmethoxy)-3,4-dihydro-naphthalen-2-ylmethyl]-piperidine-4-carboxylic acid of formula 1, and a crystalline form thereof.

IPC 8 full level
C07D 401/12 (2006.01); **A61K 31/454** (2006.01); **A61P 25/00** (2006.01); **A61P 37/00** (2006.01)

CPC (source: EP KR)
A61K 31/454 (2013.01 - EP KR); **A61P 25/00** (2018.01 - KR); **A61P 25/28** (2018.01 - KR); **A61P 29/00** (2018.01 - EP); **A61P 37/00** (2018.01 - EP KR); **C07D 401/12** (2013.01 - EP KR); **C07B 2200/13** (2013.01 - KR)

Designated contracting state (EPC)
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

Designated extension state (EPC)
BA ME

Designated validation state (EPC)
KH MA MD TN

DOCDB simple family (publication)
EP 4324827 A1 20240221; CN 117203197 A 20231208; JP 2024515177 A 20240405; KR 20220142385 A 20221021; TW 202302562 A 20230116; WO 2022220601 A1 20221020

DOCDB simple family (application)
EP 22788456 A 20220413; CN 202280028054 A 20220413; JP 2023563073 A 20220413; KR 20220045965 A 20220413; KR 2022005378 W 20220413; TW 111114263 A 20220414